Professor Ferner's research with national and international collaborators focuses on defining clinical phenotype in the neurofibromatoses, determining the natural history of optic pathway glioma and developing robust clinical and patient centred outcome measures for
monitoring novel therapies.
Not exact matches
«We wanted to develop a
novel strategy with PET imaging for non-invasively determining EGFR mutation status in real - time, predict NSCLC patients who may benefit from EGFR - TKI
therapy, and
monitor EGFR - TKI treatment outcome.»
Where research uncovers possible mechanisms for disease, those working in drug discovery can use these data to develop
novel diagnostic or
monitoring tools, to develop
therapies that address the biological pathways concerned, or to develop companion diagnostics to ensure that new — or existing —
therapies are targeted at the correct subgroup of patients.
He has extensive experience with the development of experimental vaccines for both genital herpes and HIV, and his lab has pioneered
novel tests for diagnosing and
monitoring therapies for viral infections.
Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine
Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and
Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management:
Novel Therapeutics and Management Options Targeting Radionuclide
Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?
Personalized Blood Test
Monitors Success Of Cancer
Therapies Johns Hopkins Kimmel Cancer Center researchers developed a
novel test to measure tumor - derived DNA in the bloodstream.
12 Scientific Sessions Radiochemistry: Imaging of Cancer Other Tumors Basic Science Summary Session One Myeloma and Other Marrow Disorders Radiopharmacy: Quality Control and Validation Radiotherapy and
Monitoring Therapy Basic Science Summary Session Two Pre-Clinical Systems Breast Cancer Prostate I: Initial Staging Quantification and Methodology of Oncology Studies
Novel Radiochemistry: Radiometals
In order to demonstrate clinical efficacy and move these
novel therapies quickly through the regulatory agencies, accurate and standardized tests need to be employed to measure and
monitor these bioengineered constructs.
This study presents case - series data on a
novel outpatient program that blends dialectical behavior
therapy (DBT) with standard eating disorder (ED) interventions (i.e., food exposure, weight
monitoring, cognitive modification, ED psychoeducation) for patients with complex and multidiagnostic ED presentations.